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AbstrAct
NTRK fusions are found at low frequencies (commonly 
<1%) in a range of common tumour types and at high 
frequencies (up to or greater than 90%) in rare cancer 
types (secretory breast carcinoma, mammary analogue 
secretory carcinoma and infantile fibrosarcoma). 
The fusions typically occur in a mutually exclusive 
fashion with other strong mitogenic drivers, and it is of 
significant importance to identify patients in order to offer 
transformative treatment with TRK inhibitors. Larotractinib 
or entrectinib have resulted in fast and durable response 
with few and reversible adverse events. Even though 
on- target resistance may occur, second generation TRK 
inhibitors are in development and have shown promising 
activity. Diagnostic strategies must be applied, considering 
available assays and specific tumour types.
IntroduCtIon
Several chromosomal rearrangements in 
tumour cells resulting in somatic gene fusions 
encoding a tyrosine kinase have been identi-
fied and such gene fusions may function as 
tumour drivers. A number of tyrosine kinase 
inhibitors (TKIs) have been approved, 
including TKIs targeting ABL, ALK and ROS1 
fusions.1 2 Pivotal studies have confirmed that 
these agents are superior to chemotherapy in 
patient harbouring these fusions.
The neurotrophic tyrosine kinase receptors, 
TRKA, TRKB and TRKC function as receptors 
for neurotrophins, regulating several aspects of 
neuronal development and function.3 These 
receptors are encoded by the NTRK1, NTRK2 
and NTRK3 genes, and oncogenic fusions may 
occur in any of the three NTRK genes, located 
on the human chromosomes 1q23.1, 9q21.33 
and 15q25.3, respectively. The fusion tran-
scripts encode a constitutive active tyrosine 
kinase domain, comprising the N- terminus of 
the fusion partner joined to the C- terminus of 
the TRK protein.4
TKIs targeting TRK are novel therapeutic 
approaches for the treatment of patients with 
tumours harbouring NTRK gene fusions.
FrequenCy oF ntrK gene FusIons
NTRK gene fusions are rare in common solid 
tumours with a frequency of <1%, but occur 
more frequently in some rare paediatric and 
adult tumour types, with a frequency of up to 
100% in infantile fibrosarcoma and secretory 
breast cancer5 6 (table 1). The fusions are more 
common in the NTRK1 and NTRK3 genes, and 
less frequent in NTRK2, and over 60 different 
5′ partner genes have been reported.5
trK InhIbItors
Larotrectinib is a highly selective, orally 
administered inhibitor of TRKA, TRKB 
and TRKC, with IC50 values in the range of 
5.3–11.5 nM.7 Safety and activity data have 
been obtained from patients treated with laro-
trectinib across three studies: an adult phase 
I trial, a paediatric phase I–II trial (SCOUT), 
and the adult and adolescent phase II basket 
trial (NAVIGATE). A total of 159 patients have 
been evaluable for response. Response rates 
of >75% have been reported independent 
of tumour type, age, NTRK gene and fusion 
partner. Responses are durable with a median 
duration of response (DoR) of 35.2 months, 
median progression- free survival (PFS) of 
28.2 months and a median overall survival 
(OS) of 44.4 months.8 A total of 260 patients 
were included in the safety population and 
adverse events (AEs) were generally mild 
and transient. The most frequently observed 
AEs were fatigue, cough, elevated liver func-
tion tests, constipation, nausea and dizziness. 
Dose reduction due to AEs occurred in 8% 
of both overall patients (22/260) and dose 
discontinuation due to treatment- related AEs 
occurred in 6 (2%) patients.
Entrectinib is an orally administered small 
molecule inhibitor of TRKA, TRKB, TRKC, 
ROS1, ALK, JAK2 and ACK1 kinases, with IC50 
values for the TRK kinases of <5 nM.9 Three 
clinical trials have studied safety and activity 
of entrectinib: two phase I trials (ALKA-
372–001 and STARTRK-1) and the ongoing 
phase II basket trial STARTRK-2. Response 
rates by blinded independent review was 
reported from 54 patients with NTRK fusions 
and the overall response rate (ORR) was 
59.3% with complete remission in 7.4%. The 
median DoR was 12.9 months, median PFS 
was 11.8 months and the median OS was 23.9 
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Table 1 Prevalence of NTRK fusion- positive cancers
Tumour types Prevalence (%)
Appendiceal cancer 2/97 (2)
Cholangiocarcinoma 1/28 (4)
Colorectal cancer 13/346 (4)
Colorectal cancer dMMR 10/13 (76.9)
Melanoma 1/374 (0.3)
Glioblastoma 3/115 (3)
Head and neck cancer 2/411 (0.5)
Infantile fibrosarcoma 2/4 (50)
Low- grade glioma 2/461 (0.4)
Lung adenocarcinoma 3/91 (3.3)
Mammary analogue secretory 
carcinoma
2/3 (66)
Papillary thyroid carcinoma 4/33 (12)
Paediatric high- grade glioma 28/127 (22)
Polycystic astrocytoma 3/96 (3)
Secretory breast cancer 12/13 (92)
Spitzoid melanoma 23/140 (16)
Modified from Kheder and Hong.6
dMMR, deficient mismatch repair; NTRK, neurotrophic 
tropomyosin receptor kinase.
months.10 The safety population included a total of 355 
included in the three trials. The safety profile was similar 
to larotrectinib and most adverse events were grade 1–2 
and reversible.
Both larotrectinib and entrectinib are able to penetrate 
the blood–brain barrier and intracranial response seems 
to be similar to overall response rates.
resIstanCe
Even though many patients experience long- term DoR 
treatment with TKIs may lead to acquired resistance 
and acquired on- target resistance mutations have been 
reported in patients with progression during treatment 
with receiving entrectinib or larotrectinib. Biopsies 
from such patients have identified one or more kinase 
domain mutations affecting the NTRK gene, leading 
to sterically change the drug- binding site decreasing 
the inhibitory properties and potency. These include 
amino acid substitutions involving solvent front muta-
tions, gatekeeper mutations and mutation in the xDFG 
domains, which is similar to those described for resist-
ance mutations in other classes of kinase inhibitors. 
Second- generation TRK inhibitors have been devel-
oped to overcome these mechanisms of resistance, like 
Loxo-195 and repotrectinib.
Recently, off- target mutation have been identified 
as genomic alterations converging to activation of the 
mitogen- activated protein kinase (MAPK) pathway, as 
cases with MAPK pathway- directed targeted therapy alone 
or in combination with TRK inhibition have been able to 
re- established disease control.11
testIng For ntrK FusIon
Several approaches that may be used to identify gene 
fusion in patient samples, including immunohistochem-
istry (IHC), fluorescence in situ hybridisation (FISH), 
reverse- transcriptase PCR (RT- PCR) and both DNA- based 
and RNA- based next- generation sequencing (NGS). FISH 
or RT- PCR may be used when specific well- known fusions 
are suspected, which may be the case for ETV6- NTRK3 
fusion in secretory breast cancer. However, >30 different 
fusions have been identified with three NTRK genes and 
multiple 5′ NTRK gene fusion partners have been iden-
tified. Consequently, using FISH probes for each NTRK 
gene would require three separate FISH assays per 
patient sample. IHC has been proven highly sensitive and 
specific12 for the detection of NTRK fusions and pan- TRK 
IHC is a valuable tool to identify NTRK expression. The 
advantages are the high sensitivity and specificity, the low 
cost and the fast turnaround time. However, the test may be 
false positive as it detects only transcribed and translated 
fusion proteins. DNA- based NGS is able to detect NTRK 
fusions; however, fusions involving NTRK2 and NTRK3 
with large introns may be missed. Due to chimeric nature 
of the fusion transcripts, RNA sequencing is the optimal 
method for the de novo detection of transcribed fusion 
genes, either as whole transcriptome RNA sequencing or 
targeted RNA sequencing. Sequencing libraries targets 
known fusion exons in multiple oncogenes including all 
of the three members of the NTRK family.13
strategy For testIng
Different diagnostic strategies must be applied for certain 
rare tumours with a high incidence of NTRK gene fusion 
events and more common tumour where the incidence is 
<1% of cases.
In rare cancers, NTRK fusion may be pathognomonic 
and be confirmed by FISH, whereas screening strategies 
may be used for common tumours. An ESMO working 
group has published a proposal using IHC to screen 
when NGS is not readily available, with RNA- based RNA 
as a reference for confirmation (figure 1).13
The fusions typically occur in a mutually exclusive fashion 
with other strong mitogenic drivers, that is, genetic alter-
ations affecting the most common driver genes belonging 
to the MAPK signalling pathway (Kirsten RAt Sarcoma virus 
(KRAS), Neuroblastoma RAS viral oncogene homolog 
(NRAS) and serine/threonine- protein kinase B- Raf 
(BRAF)). In lung cancer, NTRK fusion may be suspected 
in non- smokers without other activating genomic alterna-
tion after failure of standard of care. In colorectal cancer, 
it has been suggested that the fusions are more frequent 
in patients with deficient mismatch repair (dMMR) genes 
without BRAF or KRAS mutations, and such patients may be 
less responsive to checkpoint inhibitors.14
ConClusIon
Finding patients with NTRK fusion is difficult, as this 
molecular aberration is rare in common cancers and 
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Figure 1 NTRK fusion detection: the ESMO proposal.13 FISH,fluorescence in situ hybridisation; IHC, immunohistochemistry; 
NGS, next- generationsequencing; NTRK, neurotrophic tropomyosin receptor kinase; RT- PCR, reverse- transcriptasePCR
frequent only in rare cancers. However, it is important to 
consider testing patients without other activating muta-
tions. The TRK fusions are oncogenic and patients may 
have failed standard of care. Treatment with emerging 
TRK inhibitors like larotrectinib and entrectinib may 
be transformative, leading to fast and durable responses 
and few adverse event.
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